Ganaplacide

Research use only, not for human use.

Ganaplacide (KAF156, GNF-156)?is a novel antimalarial clinical candidate that shows blood schizonticidal activity with IC50 of 6-17.4 nM against P falciparum drug-sensitive and drug-resistant strains.

Ganaplacide (KAF156, GNF-156)?is a novel antimalarial clinical candidate that shows blood schizonticidal activity with IC50 of 6-17.4 nM against P falciparum drug-sensitive and drug-resistant strains; demonstrates potent therapeutic activity in mouse models of malaria with 50, 90, and 99% effective doses of 0.6, 0.9, and 1.4 mg/kg, respectively; KAF156 is completely protective as a single oral dose of 10 mg/kg in sporozoite challenge mouse model; shows the potential to treat, prevent, and block the transmission of malaria.Parasite Infection Phase 2 Clinical.

——

Animal Model:Mice (causal prophylactic rodent malaria model)Dosage:1-15 mg/kg Administration:p.o.Result:A single oral dose of 10 mg of KAF156/kg administered 2 h before infection was fully protective.

KAF156 | GNF-156

Microbiology/Virology

Parasite

Parasite

Infection

Parasite Infection

1261113-96-5

411.457

C22H23F2N5O

>98% (HPLC)

——

CC1(C)C2=NC(C3=CC=C(F)C=C3)=C(NC4=CC=C(F)C=C4)N2CCN1C(CN)=O

2-amino-1-[3-(4-fluoroanilino)-2-(4-fluorophenyl)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]ethan-1-one

(-20℃)

With Ice Pack

≥ 2 years